by Reaction Biology | Oct 1, 2024 | Blog
In the early 1990s, the discovery of promising anti-cancer agents from large-scale 60-cell line screens created an overwhelming demand for testing in traditional xenograft models. The sheer number of compounds needing evaluation far exceeded the resources available....
by Reaction Biology | Aug 29, 2024 | Blog
Reaction Biology’s Assay Formats HotSpot™ Kinase Screen Using the Gold Standard Radiometric Assay The HotSpot™ Kinase Screen uses a radiometric assay format, which directly measures kinase activity by detecting the incorporation of radioactive phosphate into the...
by Reaction Biology | Aug 26, 2024 | Blog
Testing the efficacy of lead compounds in animal models is a crucial step in preclinical drug development. Researchers have many in vivo tumor models to choose from, but selecting the right one involves considering factors such as cost, time, and technical expertise....
by John Hewitt | Aug 13, 2024 | Blog
The ATP binding site of kinases represents both a golden opportunity and a formidable challenge for drug discovery teams. This well-defined pocket serves as the docking site for potent small-molecule inhibitors, making it an attractive target for drug development....
by Reaction Biology | Jul 18, 2024 | Blog
Macrophages: Double-Edged Swords in Cancer Macrophages are phagocytic cells that eliminate pathogens and modulate adaptive immunity through cytokine secretion. However, within the TME, they exhibit phenotypic plasticity, adopting either an anti-tumor M1 or pro-tumor...
by Reaction Biology | Jul 2, 2024 | Blog
The journey of kinase drug discovery is a fascinating tale, sparked by Nobel Laureate Edmund Fischer’s discovery of protein phosphorylation. With the identification of over 500 protein kinases in the human genome, their crucial role in cellular regulation became...
